Incidence, risk factors of symptomatic venous thromboembolism and risk prediction score in hospitalized cancer patients at Ubon Ratchathani Cancer Hospital

Authors

  • Paweenrat Limpawittayakul Hematology Division, Internal Medicine Department, Ubon Ratchathani Cancer Hospital, Department of Medical services. Ministry of Public Health
  • Ponlapat Rojnuckarin Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital

DOI:

https://doi.org/10.69898/jhtm.35.2025.274743

Keywords:

cancer, venous thromboembolism, postoperative, low molecular weight heparin, heparin, wafarin

Abstract

Abstract

Introduction: Cancer patients have a higher risk for venous thromboembolism (VTE) which can lead to significant morbidity and mortality. Therefore, identifying high-risk groups for appropriate prevention is essential.

Objective: This study aimed to determine the incidence and risk factors for VTE in cancer patients receiving treatment at Ubon Ratchathani Cancer Hospital.

Methods: This prospective observational cohort study collected patient baseline data and followed-ups at 30, 60 and 90 days. Patients with suspected VTE, based on the Padua score and Caprini score, underwent Doppler ultrasonography or CT angiography. The calculated sample size was 185.

Results: Among 185 cancer patients, the incidence of VTE was 21.1%. The locations included the leg (52.6%), lungs (18.4%), neck (10.5%), abdomen (10%) and kidney (5.2%), while 2 patients died from pulmonary embolism. Patients with ECOG performance status (PS) grades 3-4 comprised 28.7%. The most common cancer type was gynecological (28.7%), followed by head and neck cancers (21.1%). Patients at stages 3-4  accounted for 68.1%, and 53% (98 patients) underwent surgery. Multivariable logistic regression analysis identified risk factors for VTE: female (adjusted odds ratio [AdjOR] = 3.87, 95% confidence interval [CI] = 1.46-10.27), ECOG PS grades 3-4 (AdjOR = 4.74, 95%CI = 1.82-12.32) and surgical intervention (AdjOR = 2.46, 95%CI = 1.01-5.96). Patients with 2 and 3 risk factors had VTE incidence rates of 19.2% and 67.9%, respectively.

Conclusion: VTE is a common complication among cancer patients. The risk factors included PS, sex and surgery. Patients with two or more of these factors should be considered for appropriate preventive measures.

Downloads

Download data is not yet available.

References

Sheth RA, Niekamp A, Quencer KB, Shamoun F, Knuttinen MG, Naidu S, et al. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther. 2017;7:S178–85.

Mulder FI, Horvath-Puho E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959-69.

Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24:3169.

Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, et al. Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA Surg. 2015;150:941-8.

Lee A, Levine M. Venous thromboembolism and cancer: Risks and outcomes. Circulation. 2003;107:I17-I21.

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158: 585–93.

Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160: 809–15.

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004;126:388S-400S.

Kakkar AK, Haas S, Wolf H, Eneke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005; 94:867-71.

Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcomebased prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006; 243:89–95.

Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89:640–6.

Björklund J, Rautiola J, Zelic R, Edgren G, Bottai M, Nilsson M, et al. Risk of Venous Thromboembolic Events After Surgery for Cancer. JAMA Netw Open. 2024;7:e2354352

Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al.A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450-7.

Downloads

Published

2025-03-28

Issue

Section

นิพนธ์ต้นฉบับ (Original article)